Human organ-on-a-chip technology as a catalyst for drug discovery

2026-06-23

PRE

Ryan Posey

Alican Özkan

Donald E. Ingber *

DOI：10.1016/j.addr.2026.115920

Original

Original request for help

Save

Abstract

En 中文

• The pharmaceutical industry faces a critical attrition crisis, with ~90% of drug candidates failing in clinical trials largely due to the inability of conventional cell cultures and animal models to accurately predict human responses. • Organ Chips enable testing of therapeutics using clinically relevant pharmacokinetic profiles and administration routes, supporting more predictive preclinical assessment of drug efficacy, toxicity, and mechanisms of resistance across a broad range of organ systems and disease states. • Integration of Organ Chips with high-throughput screening, functional genomic approaches, and artificial intelligence represents an emerging shift that enables rapid target identification, drug repurposing, and therapeutic discovery, while potentially reducing clinical failure rates.

Human organ-on-a-chip technology as a catalyst for drug discovery

Abstract

Journal

Organization

Cited Papers

Citing Papers